Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2003-03-13
2004-11-09
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S197110, C424S255100, C424S253100, C424S203100, C424S093300, C424S234100, C424S184100, C424S209100, C424S254100, C424S256100, C424S263100, C424S278100, C424S283100, C424S438000, C424S460000, C530S350000, C530S403000, C530S404000, C530S405000, C530S406000, C530S409000, C530S410000
Reexamination Certificate
active
06814971
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to immunological adjuvants. In particular, the invention relates to adjuvants which comprise an oil-in-water emulsion and a surfactant. Adjuvants of the invention are useful in a variety of vaccine formulations, including vaccines comprising bacterial or viral components.
BACKGROUND OF THE INVENTION
The generation of immunity to infectious organisms is a powerful tool in disease control. Those antigens that induce immunity to infection are known as immunogens. The protective antibody they induce may collaborate with other natural defenses to inhibit the infective process, or they may neutralize harmful products of the infective organism such as toxins.
An effective means of enhancing the antibody response is the use of an adjuvant. Thus, an adjuvant is included in a vaccine as an additive or vehicle to enhance the response to the antigen. An adjuvant may function by different mechanisms, including (1) trapping the antigen in the body to cause a slow release, (2) attracting cells of the immune system to the injection site, (3) stimulating cells of the immune system to proliferate and to become activated, and (4) improving antigen dispersion in the recipient's body.
A number of agents with diverse chemical properties have been used as adjuvants, including water-in-oil and oil-in-water emulsions, mineral salts, polynucleotides and natural substances. One adjuvant, known under the trademark AMPHIGEN™, is described in U.S. Pat. No. 5,084,269. AMPHIGEN™ adjuvant consists of de-oiled lecithin dissolved in an oil, usually light liquid paraffin. In vaccine preparations AMPHIGEN™ is dispersed in an aqueous solution or suspension of the immunizing antigen as an oil-in-water emulsion.
Problems were observed when using an AMPHIGEN™ adjuvant according to U.S. Pat. No. 5,084,269, above. For example, the lecithin in the AMPHIGEN™ does not suffice to produce a stable emulsion of the oil, thus leading to a pool or depot of oil in the injected tissues. Mineral oil can not be metabolized or removed by the animal. As a result, the oil becomes a source of severe chronic inflammation and scarring. Emulsifying the AMPHIGEN™ directly in the antigenic preparation carries the risk of damaging the antigen. Also, if the desired emulsion fails to form, the valuable antigen must be discarded.
An adjuvant useful in vaccines for animals, including humans, that is effective and solves the above problems would therefore be highly desirable.
SUMMARY OF THE INVENTION
The invention relates to an adjuvant useful for the enhancement of the immune response of an animal to an antigen. In particular, the invention relates to an adjuvant that is capable of forming an oil-in-water emulsion in a vaccine composition. The invention also relates to an adjuvant that, when used in a vaccine formulation, causes minimal inflammation and scarring at the vaccination site. The invention further relates to a vaccine formulation that contains an adjuvant of the invention. Finally, the invention relates to a method of using an adjuvant of the invention in a vaccination.
In one embodiment, the adjuvant of the invention comprises a lecithin, an oil and an amphiphilic surfactant capable of emulsifying the adjuvant, for example, a Tween or a Span surfactant. In another preferred aspect, the surfactant is Tween
80
, Tween
85
, Span
80
or Span
85
.
In another embodiment, the adjuvant of the invention comprises a lecithin, an oil and two amphiphilic surfactants capable of emulsifying the adjuvant or a vaccine composition that contains the adjuvant. In a preferred aspect, one of the two surfactants is predominantly found in the aqueous phase, for example, Tween
80
, and the other surfactant is predominantly found in the oil phase, for example, Span
80
.
A lecithin is a phosphatide. Crude preparations of lecithin may include triglycerides. For purposes of the present invention, “lecithin” encompasses both purified and crude preparations. In a preferred aspect, the lecithin is de-oiled.
Suitable oils include a mineral oil, for example, DRAKEOL™ light mineral oil.
In a further embodiment, the adjuvant of the invention contains an aqueous carrier solution, for example, a physiologically acceptable buffer, water or a saline solution.
In a preferred embodiment, the adjuvant of the invention contains a lecithin, a mineral oil, two amphiphilic surfactants and an aqueous carrier solution (e.g., saline).
In another embodiment of the invention, a method to inactivate a culture of
Bordetella bronchiseptica
(“
B. bronchiseptica
”) using formalin and glutaraldehyde is described. In another aspect, a culture of
B. bronchiseptica
is provided that was inactivated using formalin and glutaraldehyde. In yet another aspect, an antigen composition from a
B. bronchiseptica
culture is provided that was inactivated using formalin and glutaraldehyde. In yet another aspect, a vaccine composition is provided that contains an antigen composition from a
B. bronchiseptica
culture that was inactivated using formalin and glutaraldehyde.
REFERENCES:
patent: 4237115 (1980-12-01), Brinton, Jr.
patent: 4789544 (1988-12-01), Nelson et al.
patent: 4888169 (1989-12-01), Brown et al.
patent: 5019388 (1991-05-01), Brown et al.
patent: 5069901 (1991-12-01), Jones et al.
patent: 5338543 (1994-08-01), Fitzgerald et al.
patent: 5578308 (1996-11-01), Capiau et al.
patent: 5612042 (1997-03-01), Jacobs et al.
patent: 5616328 (1997-04-01), Roberts et al.
patent: 5665363 (1997-09-01), Hansen et al.
patent: 5695769 (1997-12-01), Frantz et al.
patent: 5888513 (1999-03-01), Plana Duran et al.
patent: 6013266 (2000-01-01), Segers et al.
patent: 6124432 (2000-09-01), Kawai et al.
patent: 28 16 942 (1978-11-01), None
patent: 35 17 805 (1986-11-01), None
Kume, K etal, Infection and Immunity, Properties of dermonecrotic toxin prepared from sonic extractsBordetella bronchiseptica,May 1986, vol. 52(2), pp. 370-377 (abstract only).
Dearwester Don A.
Roberts David S.
Swearingin Leroy A.
Kohn & Associates PLLC
Ling Lorraine B.
Pfizer Inc.
Portner Ginny Allen
Rehberg Edward F.
LandOfFree
Adjuvants for use in vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adjuvants for use in vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvants for use in vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3301482